

Mélanie Caron

De: Kate Lee [REDACTED]
Envoyé: 1 mars 2021 18:49
À: Martine Perreault
Cc: [REDACTED]
Objet: Re: Follow up meeting re: Biosimilar switch

Avertissement automatisé : Ce courriel provient de l'extérieur de votre organisation. Ne cliquez pas sur les liens et les pièces jointes si vous ne reconnaissez pas l'expéditeur.

Good evening Mme Perreault,
11:30 am works well for us.

Would you like us to arrange a Zoom meeting?

Best,
Kate

Kate Lee, PhD, MBA
VP, Research & Patient Programs

Sent from my iPhone

On Mar 1, 2021, at 4:55 PM, Martine Perreault [REDACTED] wrote:

Dear Ms Cowan,

Mélanie and I would be available for a 30-minute meeting with you on March 18 at 11:30 am or 1:00 pm.

Please let us know if one of these two meeting propositions would work for you.

Best regards,

Martine Perreault
Conseillère politique
Cabinet du ministre de la Santé et des Services sociaux

Édifice Catherine-De Longpré
1075, chemin Sainte-Foy, 15e étage
Québec (Québec) G1S 2M1
Téléphone : 418 266-7171 | Cellulaire : 581 992-6783
[REDACTED]

De : Mélanie Caron [REDACTED]
Envoyé : 27 février 2021 15:36
À : Susan Cowan [REDACTED]

[REDACTED]

Objet : RE: Follow up meeting re: Biosimilar switch

Bonjour,

It will be great to reconnect and discuss about the situation in Québec.
I'm away for spring break with until march 8th.
Mme Perreault will get back to you and propose a date for the meeting.

Thanks

Mélanie Caron, Pharm D, ICD.D
Conseillère spéciale en pharmacie et télésanté
Direction générale des affaires universitaires, médicales, infirmières et pharmaceutiques
Ministère de la Santé et des Services sociaux
[2021, avenue Union,](#)
[Montréal \(Québec\) H3A 2S9](#)
Tél. : [514-709-4644](#)

[REDACTED]

De : Susan Cowan [REDACTED]
Envoyé : 26 février 2021 11:53
À : Mélanie Caron [REDACTED]; Martine Perreault

[REDACTED]

Objet : Follow up meeting re: Biosimilar switch

Avertissement automatisé : Ce courriel provient de l'extérieur de votre organisation. Ne cliquez pas sur les liens et les pièces jointes si vous ne reconnaissez pas l'expéditeur.

Dear Ms. Caron,

I am Sue Cowan, the interim CEO of Crohn's and Colitis Canada. I hope this email finds you well.

I am following up on a meeting held with Crohn's and Colitis Canada's former President & CEO – Mina Mawani – and yourself on Quebec's consideration of implementing a biologic to biosimilar switch policy.

We understand that the Quebec government has been contacting gastroenterologists and other patient organizations to re-initiate consultations leading up to the government's switch policy.

As Mina mentioned, Crohn's and Colitis Canada is the only national health charity focused on research and supporting Crohn's disease and ulcerative colitis patients through education, awareness and

advocacy. In preparation for our follow up meeting, we held a roundtable of gastroenterologists and patients and have conducted surveys.

To support Quebec's decision on the switch policy, we are reaching out to request a meeting with you and/or Ms. Perreault at your earliest convenience to share this information.

We hope to work with you to support cost savings along with ensuring the health of Quebec constituents living with Crohn's disease and ulcerative colitis. We are looking forward to hearing from you.

Sincerely,

Sue

[Redacted signature block]

Please exercise caution in opening links or attachments from outside senders.